Clinical trial · Interventional
64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer
64Cu-DOTA-trastuzumab Positron Emission Tomography in Patients With Gastric Cancer
NCT01939275CI-TRIAL-00086651completedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This pilot clinical trial studies copper Cu 64 (64Cu) tetra-azacyclododecanetetra-acetic acid (DOTA)-trastuzumab positron emission tomography (PET)/computed tomography (CT) in studying patients with gastric, or stomach cancer. Diagnostic procedures, such as copper Cu 64-DOTA-trastuzumab PET/CT, may help doctors study the characteristics of tumors and choose the best treatment.
Conditions
Conditions (13)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenocarcinoma of the Gastroesophageal Junction | Gastroesophageal Junction Adenocarcinoma | ALIAS | 0.90 |
| Diffuse Adenocarcinoma of the Stomach | Gastric Diffuse Adenocarcinoma | ALIAS | 0.90 |
| Intestinal Adenocarcinoma of the Stomach | Gastric Intestinal-Type Adenocarcinoma | ALIAS | 0.90 |
| Mixed Adenocarcinoma of the Stomach | Gastric Neoplasm | PROBABILISTIC | 0.70 |
| Recurrent Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Stage IA Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Stage IB Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Stage IIA Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Computed Tomography | Procedure | — | UNRESOLVED |
| copper Cu 64-DOTA-trastuzumab | Radiation | — | UNRESOLVED |
| laboratory biomarker analysis | Other | — | UNRESOLVED |
| positron emission tomography | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Diagnostic (copper Cu 64-DOTA-trastuzumab PET scan)
- description
- Patients receive copper Cu 64-DOTA-trastuzumab IV on day 1 and then undergo PET/CT scan on days 2 or 3.
- interventionNames
- Radiation: copper Cu 64-DOTA-trastuzumab
- Device: positron emission tomography
- Other: laboratory biomarker analysis
- Procedure: Computed Tomography
Primary outcomes (1)
- measure
- Number of HER2 Negative, Positive, or Equivocal Participants With Either Negative or Positive Tumor Readings
- timeFrame
- Up to 1 year
- description
- The reading of the 64CuDOTA-trastuzumab-PET imaging of the study subjects were performed by two radiologists, one who read the first scan and the second nuclear radiologist read the remaining seven scans. To eliminate potential bias, the second nuclear radiologist was blinded to the HER2 status of the tumors as well as the location of the tumor until radiolabeled uptake was measured. XD (version 3.6; Miranda Medical) was used for image analysis.Tumor visualized as "hot" relative to adjacent tissue reported per radiologist as negative, positive, equivocal or unknown.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient must have a histologic diagnosis of gastric or gastroesophageal junction adenocarcinoma * Two patients must be HER2 3+ by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) positive * Either the primary tumor or at least one of the metastatic lesions must be \>= 2 cm * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Life expectancy of \>= 3 months * Women of childbearing potential must have a negative serum pregnancy test within 14 days of copper Cu 64-DOTA administrations and must have agreed to use an effective contraceptive method; women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for four months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately * CT/magnetic resonance imaging (MRI) scan must be obtained within 4 weeks prior to study entry * Patients must have normal cardiac ejection fraction * All subjects must have the ability to understand and the willingness to sign a written informed consent * All toxicities should recover to grade 0 or 1 prior to day 1 Exclusion Criteria: * Impaired cardiac function including any one of the following: complete left bundle branch block or use of a permanent cardiac pacemaker, congenital long QT syndrome, presence of ventricular tachyarrhythmias, clinically significant resting bradycardia (\< 50 beats per minute), QT interval corrected by Fridericia's formula (QTcF) \> 450 msec on screening electrocardiogram (ECG), or right bundle branch block + left anterior hemiblock (bifascicular block) * Presence of atrial fibrillation * Previous history of angina pectoris or acute myocardial infarction (MI) within 6 months * Congestive heart failure (New York Heart Association functional classification III-IV) * Uncontrolled hypertension (mmHg \> 160 systolic or \> 90 diastolic) * Patients should not have active infections or concurrent neoplastic disease except for skin cancer * Patients may not be receiving any other investigational agents * At the time of enrollment, patients may not have received any biological, chemotherapy, or radiation therapy * Patients who may not have received trastuzumab within the prior 6 months for any other reason * Patients who are pregnant * Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study
References
Publications (0)
Data not yet available
No reference posted for this study.